Daily Endocrinology Research Analysis
Three papers stand out today in endocrinology and metabolism: a phase 3 Lancet trial shows robust weight loss with once-daily oral GLP-1 receptor agonist orforglipron in adults with type 2 diabetes; a Nature Communications study challenges the prevailing paradigm by demonstrating that fructose (and follistatin) can acutely drive MASLD even with complete hepatic insulin resistance; and a PNAS mechanistic study identifies Neuroplastin-55 as a receptor for MANF that promotes adipose browning and pr
Summary
Three papers stand out today in endocrinology and metabolism: a phase 3 Lancet trial shows robust weight loss with once-daily oral GLP-1 receptor agonist orforglipron in adults with type 2 diabetes; a Nature Communications study challenges the prevailing paradigm by demonstrating that fructose (and follistatin) can acutely drive MASLD even with complete hepatic insulin resistance; and a PNAS mechanistic study identifies Neuroplastin-55 as a receptor for MANF that promotes adipose browning and protects against diet-induced obesity.
Research Themes
- Oral incretin pharmacotherapy for obesity in type 2 diabetes
- Fructose-driven pathogenesis of MASLD independent of insulin signaling
- Adipose browning via receptor-ligand biology (Np55–MANF axis)
Selected Articles
1. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
In a 72-week, multicenter, double-blind phase 3 trial (n=1613), once-daily oral orforglipron (6–36 mg) produced statistically superior bodyweight reduction versus placebo as an adjunct to lifestyle modification in adults with type 2 diabetes and overweight/obesity. Completion was high (89.5%), and adverse events were consistent with the GLP-1RA class profile.
Impact: This is the first large, late-phase RCT to demonstrate robust weight loss with a non-peptide, once-daily oral GLP-1RA in type 2 diabetes, addressing adherence and access barriers to injectable incretins.
Clinical Implications: Orforglipron could expand incretin-based obesity management for type 2 diabetes to an oral option, potentially improving adherence and facilitating earlier combination strategies; safety monitoring should follow class-consistent GI AEs.
Key Findings
- Adults with T2D and BMI ≥27 kg/m2 randomized to orforglipron (6, 12, or 36 mg) had statistically greater bodyweight reduction versus placebo at 72 weeks.
- High study completion (89.5%) across 136 sites in 10 countries supports feasibility and tolerability.
- Adverse events were consistent with GLP-1RA class effects, with no unexpected safety signals reported.
Methodological Strengths
- Phase 3, double-blind, randomized, multicenter design with large sample size (n=1613)
- Dose-ranging evaluation with lifestyle counseling standardization
Limitations
- Industry-sponsored trial; detailed glycemic and cardiometabolic secondary outcomes not fully described in abstract
- Generalizability may vary across populations and comorbidities; long-term cardiovascular outcomes not reported
Future Directions: Head-to-head comparisons with injectable GLP-1RAs, durability beyond 72 weeks, cardiometabolic outcomes, and combination with SGLT2 inhibitors or tirzepatide-like agents.
BACKGROUND: Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. METHODS: This 72-week, phase 3, double-blind, placebo-controlled trial was conducted across 136 sites in ten countries. Participants with a BMI of 27 kg/m FINDINGS: From June 5, 2023, to Feb 15, 2024, 2859 participants were screened, and 1613 (757 [46·9%] female) were randomly assigned, following a dose-escalation phase, to receive orforglipron 6 mg (n=329), 12 mg (n=332), 36 mg (n=322), or placebo (n=630), as an adjunct to lifestyle modification; 1444 (89·5%) completed the study. Baseline bodyweight was 101·4 kg (SD 22·5), BMI 35·6 kg/m
2. Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.
Using a genetic mouse model lacking hepatic insulin signaling (LDKO), the authors show that fructose-enriched diets rapidly induce MASLD despite complete hepatic insulin resistance. Mechanistically, fructose enhanced hepatic re-esterification of circulating fatty acids, overturning the assumption that insulin-driven de novo lipogenesis is required for steatosis initiation.
Impact: This study challenges a core paradigm in MASLD pathogenesis and provides a mechanistic basis linking dietary fructose and hepatic steatosis independent of insulin signaling.
Clinical Implications: Supports prioritizing fructose restriction in MASLD prevention and management, even in insulin-resistant states; suggests new therapeutic targets (e.g., pathways governing hepatic re-esterification and follistatin signaling).
Key Findings
- LDKO mice with complete hepatic insulin resistance acutely developed MASLD on fructose-enriched diets (GAN or high-fructose).
- Fructose potentiated hepatic re-esterification of circulating fatty acids in LDKO mice, mechanistically driving steatosis.
- Findings overturn the assumption that insulin-stimulated de novo lipogenesis is essential for MASLD initiation.
Methodological Strengths
- Use of a genetic model (LDKO) ensuring complete loss of hepatic insulin signaling
- Dietary interventions (GAN, high-fructose) enabling causal inference on fructose effects
Limitations
- Preclinical mouse study; human translation and dose–response to dietary fructose require validation
- Abstract does not detail chronic outcomes or fibrosis progression
Future Directions: Human metabolic studies testing fructose restriction in insulin-resistant MASLD; investigation of follistatin and re-esterification enzymes as therapeutic targets; long-term outcomes.
MASLD (metabolic-associated steatotic liver disease) and MASH (steatohepatitis) are closely associated with hepatic IR (insulin resistance) and T2D. Regardless, insulin-stimulated hepatic lipogenesis is considered essential for MASLD development, as mouse models of complete hepatic IR become diabetic without MASLD when fed high-fat diets. Challenging this notion, we found that male LDKO mice lacking hepatic insulin receptor substrates acutely developed MASLD if fed a fructose-enriched "MASH diet" (GAN) or high-fructose diet. Fructose potentiated hepatic re-esterification of abundant circulating fatty acids in LDKO mice, evidenced by excess
3. Neuroplastin-55 is a receptor of Manf and protects against diet-induced obesity by promoting adipose browning.
The study identifies Neuroplastin-55 (Np55) as a receptor for MANF in adipose tissue. Np55 is upregulated in obese human and mouse adipose tissue, and adipocyte-specific Np55 loss impairs WAT browning/thermogenesis and protection against diet-induced obesity, positioning the MANF–Np55 axis as a therapeutic target.
Impact: Receptor identification for a browning factor (MANF) provides a concrete target to pharmacologically enhance adipose thermogenesis, with translational relevance for obesity.
Clinical Implications: Therapeutics that agonize MANF–Np55 signaling could promote adipose browning and energy expenditure; biomarker-driven stratification using Np55 expression may be explored.
Key Findings
- Np55 expression is markedly upregulated in adipose tissue from obese humans and mice.
- Adipocyte-specific Np55 knockout impairs WAT browning/thermogenesis and protection against diet-induced obesity.
- Np55 functions as a receptor for MANF, defining a ligand–receptor axis that regulates adipose browning.
Methodological Strengths
- Cross-species validation (human and mouse adipose) with adipocyte-specific knockout
- Receptor–ligand mechanistic elucidation supporting causality
Limitations
- Preclinical; absence of pharmacologic agonists/antagonists tested in vivo in the abstract
- Translational dose–response and safety in humans remain unknown
Future Directions: Develop small molecules or biologics targeting MANF–Np55; assess metabolic efficacy and safety in large animals and early-phase clinical trials; explore Np55 expression as a patient-selection biomarker.
The browning of white adipose tissue (WAT) enhances thermogenesis and holds great potential in obesity treatment. Membrane receptors have been proven as essential factors during WAT browning. In this study, we found that transmembrane receptor neuroplastin-55 (Np55) was markedly upregulated in the adipose tissue of both obese individuals and mice. Fat-specific Np55 knockout (Np55